Combination treatment for B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study tests two drugs, pirtobrutinib and sonrotoclax, given together to treat certain types of B-cell lymphoma that have come back or not responded to other treatments. The combination may help shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have one of these types of lymphoma: transformed large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or marginal zone lymphoma, which has returned or not responded to prior therapy.
- You need to have had at least one prior treatment for your lymphoma (for certain types, this prior treatment must include specific drugs).
- You must have at least one measurable tumor on a PET/CT scan done within the last month.
- Your overall health must be fairly good (able to care for yourself) and your heart, liver, kidney, and bone marrow function must be adequate.
- If you are of childbearing potential, you must agree to use effective contraception during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
This trial tests a combination of targeted drugs for people with a type of lymphoma (DLBCL) that has come back or not responded after previous treatment with a BTK inhibitor. The goal is to see if adding a drug called pirtobrutinib to standard chemotherapy helps control the cancer.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
Hear when a new Richter Transformation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.